Summary
AbbVie Inc. reported strong financial results for the year ended December 31, 2025, with worldwide net revenues reaching $61.2 billion, a 8.6% increase over the prior year. This growth was primarily driven by its immunology products, Skyrizi and Rinvoq, which collectively accounted for approximately 42% of total net revenues and demonstrated significant year-over-year increases of 49.9% and 39.1%, respectively. The company experienced a substantial decline in Humira revenues (-49.5%) due to ongoing biosimilar competition. AbbVie continued its strategic investments in research and development, with pipeline advancements across its core therapeutic areas, including notable progress in neuroscience and oncology. The company's financial health remains robust, with operating earnings of $15.1 billion and strong cash flow from operations of $19.0 billion. AbbVie also actively managed its capital structure, including debt issuance and repayment, and returned value to shareholders through dividends, which were increased to $1.73 per share quarterly. The company also announced a voluntary agreement with the U.S. government, pledging significant investment in U.S.-based R&D and capital projects, in exchange for a three-year exemption from certain tariffs and price mandates. Despite these positive trends, AbbVie faces ongoing risks related to patent expirations, increasing biosimilar competition, and evolving regulatory and pricing pressures, particularly from the Inflation Reduction Act impacting key products like Imbruvica, Vraylar, and Botox.
Financial Highlights
56 data points| Revenue | $61.16B |
| Cost of Revenue | $18.20B |
| Gross Profit | $42.96B |
| SG&A Expenses | $14.01B |
| Operating Expenses | $46.09B |
| Operating Income | $15.07B |
| Interest Expense | $2.89B |
| Net Income | $4.23B |
| EPS (Basic) | $2.37 |
| EPS (Diluted) | $2.36 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1AbbVie's net revenues grew 8.6% to $61.2 billion in 2025, driven by strong performance in immunology. Skyrizi and Rinvoq showed robust growth of 49.9% and 39.1% respectively, becoming major revenue drivers. Humira revenue declined significantly by 49.5% due to biosimilar competition.
- 2The company generated $19.0 billion in cash flow from operations, underscoring strong financial health.
- 3AbbVie increased its quarterly dividend to $1.73 per share, demonstrating a commitment to returning capital to shareholders.
- 4Significant R&D investments continue, with a pipeline of approximately 90 compounds, devices, or indications in development.
- 5The company is strategically expanding its capabilities with new facilities and announced a voluntary agreement with the U.S. government involving substantial investment in U.S. R&D and capital projects.
- 6AbbVie is subject to ongoing risks including patent expirations, biosimilar competition, and pricing pressures from regulatory actions like the Inflation Reduction Act.